

CITATION REPORT

List of articles citing

Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder

DOI: 10.1093/brain/awp336
Brain, 2010, 133, 655-70.

Source: <https://exaly.com/paper-pdf/48800287/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
334	Approach to refractory childhood seizures. 2010 , 7, 497-506		4
333	Defining neurogenetic phenotypes (or how to compare needles in haystacks). <i>Brain</i> , 2010 , 133, 649-51	11.2	8
332	GLUT1-ous maximus epilepticus: the expanding phenotype of GLUT-1 mutations and epilepsy. 2010 , 75, 390-1		13
331	Glucose Transporter 1 Deficiency: CNS Glucose Levels & Symptoms. 2010 , 24, 12-12		
330	'Looks like epilepsy to me!'. <i>Brain</i> , 2010 , 133, 651-2	11.2	
329	Absence of mutation in the SLC2A1 gene in a cohort of patients with alternating hemiplegia of childhood (AHC). 2010 , 41, 267-9		11
328	Dietary treatment of epilepsy: rebirth of an ancient treatment. 2011 , 45, 370-8		13
327	SLC2A1 gene analysis of Japanese patients with glucose transporter 1 deficiency syndrome. 2011 , 56, 846-51		12
326	[Movement disorders and neurometabolic diseases]. <i>Revue Neurologique</i> , 2011 , 167, 123-34	3	5
325	Stomatin-deficient cryohydrocytosis results from mutations in SLC2A1: a novel form of GLUT1 deficiency syndrome. 2011 , 118, 5267-77		61
324	Dietary therapies for epilepsy: future research. 2011 , 22, 17-22		33
323	Video/EEG recording of myoclonic absences in GLUT1 deficiency syndrome with a hot-spot R126C mutation in the SLC2A1 gene. 2011 , 21, 200-2		13
322	Choréathéses paroxystiques. 2011 , 8, 1-5		
321	Epilepsy beginning in infancy. 5-28		
320	Milder phenotypes of glucose transporter type 1 deficiency syndrome. 2011 , 53, 664-8		12
319	A modified Atkins diet is promising as a treatment for glucose transporter type 1 deficiency syndrome. 2011 , 53, 658-63		107
318	Refractory absence epilepsy associated with GLUT-1 deficiency syndrome. <i>Epilepsia</i> , 2011 , 52, 1021-4	6.4	10

317	The ketogenic diet for Dravet syndrome and other epileptic encephalopathies: an Italian consensus. <i>Epilepsia</i> , 2011 , 52 Suppl 2, 83-9	6.4	29
316	"Benign" myoclonic epilepsy of infancy as the initial presentation of glucose transporter-1 deficiency. 2011 , 13, 300-3		6
315	Cerebrovascular disorders: molecular insights and therapeutic opportunities. 2011 , 14, 1390-7		66
314	Dystonic tremor caused by mutation of the glucose transporter gene GLUT1. 2011 , 34, 483-8		20
313	[New developments in epileptogenesis and therapeutic perspectives]. 2011 , 82, 978-85		2
312	Differential diagnosis of chorea. 2011 , 11, 385-95		23
311	Glut1 deficiency syndrome and erythrocyte glucose uptake assay. 2011 , 70, 996-1005		63
310	"Gluing" phenotypes together: the case of GLUT1. 2011 , 77, 934-5		2
309	Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. 2011 , 77, 959-64		93
308	The patient with infantile seizures. 2011 , 23, 693-9		
307	The paroxysmal dyskinesias. 2011 , 476-495		
306	Glucose transporter-1 (GLUT1) deficiency syndrome: diagnosis and treatment in late childhood. 2012 , 43, 168-71		12
305	Glucose transporter type I deficiency causing mitochondrial dysfunction. 2012 , 27, 796-8		1
304	Epilepsy in children--when should we think neurometabolic disease?. 2012 , 27, 663-71		13
303	Diagnostik und Behandlung zerebraler Anfälle in der Neonatalperiode. 2012 , 01, 129-145		
302	Classification of epilepsies and seizures: historical perspective and future directions. 2012 , 107, 99-111		15
301	First report of glucose transporter 1 deficiency syndrome in Korea with a novel splice site mutation. 2012 , 506, 380-2		3
300	A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'. 2012 , 6, 224-8		5

299	Early onset absence epilepsy: 1 in 10 cases is caused by GLUT1 deficiency. <i>Epilepsia</i> , 2012 , 53, e204-7	6.4	75
298	Overview of primary monogenic dystonia. 2012 , 18 Suppl 1, S158-61		17
297	GLUT1 mutations are a rare cause of familial idiopathic generalized epilepsy. 2012 , 78, 557-62		76
296	Glucose transporter 1 deficiency in the idiopathic generalized epilepsies. 2012 , 72, 807-15		98
295	Allelic variations of glut-1 deficiency syndrome: the chinese experience. 2012 , 47, 30-4		7
294	Treatable inborn errors of metabolism causing intellectual disability: a systematic literature review. 2012 , 105, 368-81		133
293	GLUT1 deficiency syndrome in clinical practice. <i>Epilepsy Research</i> , 2012 , 100, 272-7	3	94
292	GLUT1 deficiency syndrome as a cause of encephalopathy that includes cognitive disability, treatment-resistant infantile epilepsy and a complex movement disorder. 2012 , 55, 332-4		10
291	Databases for neurogenetics: introduction, overview, and challenges. 2012 , 33, 1311-4		3
290	Common Genetic and Neurocutaneous Disorders in Childhood Epilepsy. 2012 , 59-72		
289	Disorders of Glucose Transport. 2012 , 175-183		1
288	Introduction to Epilepsy. 299-303		
287	Introduction to Epilepsy. 107-118		
286	Glut1 deficiency: when to suspect and how to diagnose?. <i>European Journal of Paediatric Neurology</i> , 2012 , 16, 3-9	3.8	41
285	Episodic neurologic disorders: syndromes, genes, and mechanisms. 2013 , 36, 25-50		16
284	Sugar for the brain: the role of glucose in physiological and pathological brain function. 2013 , 36, 587-97		695
283	Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). 2013 , 13, 342		129
282	Episodic movement disorders: from phenotype to genotype and back. 2013 , 13, 379		9

281	Good outcome in patients with early dietary treatment of GLUT-1 deficiency syndrome: results from a retrospective Norwegian study. 2013 , 55, 440-7	45
280	Inborn errors of metabolism causing epilepsy. 2013 , 55, 23-36	52
279	GLUT1 deficiency syndrome 2013: current state of the art. 2013 , 22, 803-11	130
278	A case of severe progressive early-onset epileptic encephalopathy: unique GABAergic interneuron distribution and imaging. 2013 , 327, 65-72	2
277	Épilepsie de début précoce, mouvements anormaux tardifs chez une femme de 37ans. 2013 , 4, 124-130	
276	Treatment of epileptic encephalopathies. 2013 , 27, 175-84	53
275	The genetics of dystonia: new twists in an old tale. <i>Brain</i> , 2013 , 136, 2017-37	11.2 80
274	Chorea. 2013 , 19, 1242-63	4
273	Cerebrospinal fluid analysis in the workup of GLUT1 deficiency syndrome: a systematic review. 2013 , 70, 1440-4	82
272	Glut1 deficiency syndrome and novel ketogenic diets. 2013 , 28, 1045-8	41
271	Acute ataxia in children: approach to clinical presentation and role of additional investigations. 2013 , 44, 127-41	24
270	No Mutation in the SLC2A3 Gene in Cohorts of GLUT1 Deficiency Syndrome-Like Patients Negative for SLC2A1 and in Patients with AHC Negative for ATP1A3. 2014 , 12, 115-20	3
269	Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet. 2013 , 28, 1439-42	38
268	Management of refractory neonatal seizures. 2014 , 17	1
267	Ketogenic dietary therapy for epilepsy and other disorders: current perspectives. 2014 , 25	4
266	Severe familial paroxysmal exercise-induced dyskinesia. 2014 , 261, 2009-15	7
265	Association between coenzyme Q10 and glucose transporter (GLUT1) deficiency. 2014 , 14, 284	13
264	Does ketogenic diet improve cognitive function in patients with GLUT1-DS? A 6- to 17-month follow-up study. 2014 , 39, 111-5	31

263	Suppression of conformation-compromised mutants of Salmonella enterica serovar Typhimurium MelB. 2014 , 196, 3134-9		18
262	A diagnostic approach for cerebral palsy in the genomic era. 2014 , 16, 821-44		65
261	Focal epilepsy in glucose transporter type 1 (Glut1) defects: case reports and a review of literature. 2014 , 261, 1881-6		20
260	Serum glucose adjusted cut-off values for normal cerebrospinal fluid/serum glucose ratio: implications for clinical practice. 2014 , 52, 1335-40		13
259	GLUT1 deficiency syndrome: an update. <i>Revue Neurologique</i> , 2014 , 170, 91-9	3	48
258	[De Vivo disease. GLUT-1 deficiency syndrome: a case report]. 2014 , 21, 302-5		1
257	Hypoglycemia in the newborn and infant. 2014 , 157-185.e2		5
256	GLUT1 deficiency syndrome into adulthood: a follow-up study. 2014 , 261, 589-99		50
255	Crystal structure of the human glucose transporter GLUT1. 2014 , 510, 121-5		457
254	A three-year-old boy with glucose transporter type 1 deficiency syndrome presenting with episodic ataxia. 2014 , 50, 99-100		14
253	Acute Pediatric Neurology. 2014 ,		
252	The many faces of Glut1 deficiency syndrome. 2014 , 29, 349-59		21
251	Efficient strategy for the molecular diagnosis of intellectual disability using targeted high-throughput sequencing. 2014 , 51, 724-36		177
250	A Cause of Permanent Ketosis: GLUT-1 Deficiency. 2015 , 18, 79-83		7
249	Brain glucose transporters: implications for neurologic disease. 2014 , 82, 1374-9		67
248	Occasional seizures, epilepsy, and inborn errors of metabolism. 2014 , 13, 727-39		33
247	Klinisches Spektrum des Glucosetransporter-Typ-1-Defizienz-Syndroms. 2014 , 27, 186-190		1
246	Dietary Treatments and New Therapeutic Perspective in GLUT1 Deficiency Syndrome. 2014 , 16, 291		29

245	Paroxysmal dyskinesias revisited: a review of 500 genetically proven cases and a new classification. 2014 , 29, 1108-16		123
244	Long-term effects of a ketogenic diet on body composition and bone mineralization in GLUT-1 deficiency syndrome: a case series. 2014 , 30, 726-8		31
243	Alternating hemiplegia of childhood with a de novo mutation in ATP1A3 and changes in SLC2A1 responsive to a ketogenic diet. 2014 , 50, 377-9		20
242	Epilepsy, energy deficiency and new therapeutic approaches including diet. 2014 , 144, 192-201		23
241	Occurrence of GLUT1 deficiency syndrome in patients treated with ketogenic diet. 2014 , 32, 76-8		10
240	Movement Disorders in Glucose Transporter Type 1 Deficiency. 2015 , 13, 168-173		
239	Neutropenia responsive to ketogenic diet in an infant with GLUT1 deficiency syndrome. 2015 , 02, 137-140		
238	Genetic Counselling in Epilepsy. 2015 , 323-343		
237	GLUT1 deficiency syndrome and ketogenic diet therapies: missing rare but treatable diseases?. 2015 , 57, 896-7		7
236	Favourable response to ketogenic dietary therapies: undiagnosed glucose 1 transporter deficiency syndrome is only one factor. 2015 , 57, 969-76		7
235	Epileptic activity is a surrogate for an underlying etiology and stopping the activity has a limited impact on developmental outcome. <i>Epilepsia</i> , 2015 , 56, 1477-81	6.4	26
234	A Case of Progressive Chorea Resulting From GLUT1 Deficiency. 2015 , 2, 424-425		2
233	The role of SLC2A1 mutations in myoclonic astatic epilepsy and absence epilepsy, and the estimated frequency of GLUT1 deficiency syndrome. <i>Epilepsia</i> , 2015 , 56, e203-8	6.4	52
232	Molecular Dynamics Simulations of the Human Glucose Transporter GLUT1. 2015 , 10, e0125361		37
231	A Protein Kinase C Phosphorylation Motif in GLUT1 Affects Glucose Transport and is Mutated in GLUT1 Deficiency Syndrome. 2015 , 58, 845-53		68
230	The genetics of the epilepsies. 2015 , 15, 39		22
229	The ketogenic diet in pharmaco-resistant childhood epilepsy. 2015 , 15, 621-8		46
228	In vitro nanobody discovery for integral membrane protein targets. 2014 , 4, 6760		29

227	Obtaining genetic testing in pediatric epilepsy. <i>Epilepsia</i> , 2015 , 56, 1505-14	6.4	28
226	Long-term clinical course of Glut1 deficiency syndrome. 2015 , 30, 160-9		58
225	When should clinicians search for GLUT1 deficiency syndrome in childhood generalized epilepsies?. <i>European Journal of Paediatric Neurology</i> , 2015 , 19, 170-5	3.8	7
224	Diagnosis and treatment of chorea syndromes. 2015 , 15, 514		56
223	New Paradigm for the Treatment of Glucose Transporter 1 Deficiency Syndrome: Low Glycemic Index Diet and Modified High Amylopectin Cornstarch. 2015 , 53, 243-6		6
222	From splitting GLUT1 deficiency syndromes to overlapping phenotypes. 2015 , 58, 443-54		35
221	Glucose Transporter 1 Deficiency: A Treatable Cause of Opsoclonus and Epileptic Myoclonus. 2015 , 53, 364-6		6
220	Clinical reasoning: novel GLUT1-DS mutation: refractory seizures and ataxia. 2015 , 84, e111-4		3
219	Treatable causes of cerebellar ataxia. 2015 , 30, 614-23		28
218	Movement Disorder Genetics. 2015 ,		
217	Do Glut1 (glucose transporter type 1) defects exist in epilepsy patients responding to a ketogenic diet?. <i>Epilepsy Research</i> , 2015 , 114, 47-51	3	5
216	Decade in review-movement disorders: tracking the pathogenesis of movement disorders. 2015 , 11, 618-9		2
215	A Novel Frameshift Mutation in SLC2A1 Associated with a Mild form of Glucose Transporter Type 1-Related Movement Disorder. 2015 , 13, 088-091		
214	Overlap of autism spectrum disorder and glucose transporter 1 deficiency syndrome associated with a heterozygous deletion at the 1p34.2 region. 2015 , 356, 212-4		4
213	The Effects of Ketogenic Diet on Seizures, Cognitive Functions, and Other Neurological Disorders in Classical Phenotype of Glucose Transporter 1 Deficiency Syndrome. 2015 , 46, 313-20		11
212	Mutational and functional analysis of Glucose transporter I deficiency syndrome. 2015 , 116, 157-62		5
211	Axons to Exons: the Molecular Diagnosis of Rare Neurological Diseases by Next-Generation Sequencing. 2015 , 15, 64		22
210	Genetics of Paroxysmal Dyskinesia. 2015 , 191-211		1

209	The clinical and genetic heterogeneity of paroxysmal dyskinesias. <i>Brain</i> , 2015 , 138, 3567-80	11.2	96
208	Nationwide survey of glucose transporter-1 deficiency syndrome (GLUT-1DS) in Japan. 2015 , 37, 780-9		29
207	Sporadic and familial glut1ds Italian patients: A wide clinical variability. 2015 , 24, 28-32		23
206	A novel SLC2A1 mutation linking hemiplegic migraine with alternating hemiplegia of childhood. 2015 , 35, 10-5		20
205	Episodic and electrical nervous system disorders caused by nonchannel genes. 2015 , 77, 525-41		7
204	Exogenous Ketone Supplements Reduce Anxiety-Related Behavior in Sprague-Dawley and Wistar Albino Glaxo/Rijswijk Rats. 2016 , 9, 137		50
203	Current concepts in the treatment of hereditary ataxias. 2016 , 74, 244-52		16
202	Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force. 2016 , 31, 436-57		148
201	Evaluation of non-coding variation in GLUT1 deficiency. 2016 , 58, 1295-1302		19
200	Use of modified Atkins diet in glucose transporter type 1 deficiency syndrome. 2016 , 58, 1193-1199		20
199	Paroxysmal Nonepileptic Events in Glut1 Deficiency. 2016 , 3, 607-610		8
198	A Case of Glucose Transporter 1 Deficiency Syndrome. 2016 , 05, 034-036		
197	Paroxysmal movement disorders: An update. <i>Revue Neurologique</i> , 2016 , 172, 433-445	3	40
196	[Childhood absence epilepsy: An update]. 2016 , 23, 1176-1183		2
195	Improving diagnosis for congenital cataract by introducing NGS genetic testing. 2016 , 5,		14
194	Novel treatment perspectives from advances in understanding of genetic epilepsy syndromes. 2016 , 4, 485-490		
193	Atypical Manifestations in Glut1 Deficiency Syndrome. 2016 , 31, 1174-80		20
192	Disorders of Movement. 2016 ,		8

191	Outcome of ketogenic diets in GLUT1 deficiency syndrome in Japan: A nationwide survey. 2016 , 38, 628-37	24
190	Epileptic Encephalopathy in Childhood: A Stepwise Approach for Identification of Underlying Genetic Causes. 2016 , 83, 1164-74	8
189	Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. 2016 , 87, 550-3	60
188	Glut1 deficiency syndrome: Absence epilepsy and La Soupe du Jour. 2016 , 16, 50-2	3
187	A semiquantitative metric for evaluating clinical actionability of incidental or secondary findings from genome-scale sequencing. 2016 , 18, 467-75	56
186	Near-critical GLUT1 and Neurodegeneration. 2017 , 95, 2267-2274	19
185	Genetic Variants Identified from Epilepsy of Unknown Etiology in Chinese Children by Targeted Exome Sequencing. 2017 , 7, 40319	33
184	Pediatric Autoimmune Epileptic Encephalopathies. 2017 , 32, 418-428	9
183	Upstream SLC2A1 translation initiation causes GLUT1 deficiency syndrome. 2017 , 25, 771-774	11
182	GLUT1-deficiency syndrome: Report of a four-generation Norwegian family with a mild phenotype. 2017 , 70, 1-4	10
181	Gene and Variant Annotation for Mendelian Disorders in the Era of Advanced Sequencing Technologies. <i>Annual Review of Genomics and Human Genetics</i> , 2017 , 18, 229-256	9.7 32
180	Clinical Aspects of Glucose Transporter Type 1 Deficiency: Information From a Global Registry. 2017 , 74, 727-732	18
179	The face of Glut1-DS patients: A 3D Craniofacial Morphometric Analysis. 2017 , 30, 644-652	13
178	Ketone Bodies as a Possible Adjuvant to Ketogenic Diet in PDHc Deficiency but Not in GLUT1 Deficiency. 2018 , 38, 53-59	5
177	A simple blood test expedites the diagnosis of glucose transporter type 1 deficiency syndrome. 2017 , 82, 133-138	17
176	Paroxysmal eye-head movements in Glut1 deficiency syndrome. 2017 , 88, 1666-1673	30
175	Novel mutation in a patient with late onset GLUT1 deficiency syndrome. 2017 , 39, 352-355	1
174	Triheptanoin for the treatment of brain energy deficit: A 14-year experience. 2017 , 95, 2236-2243	28

173	Rare GABRA3 variants are associated with epileptic seizures, encephalopathy and dysmorphic features. <i>Brain</i> , 2017 , 140, 2879-2894	11.2	24
172	Avian and Mammalian Facilitative Glucose Transporters. 2017 , 6,		17
171	JIMD Reports, Volume 38. 2018 ,		
170	Abnormal white matter: Expanding the GLUT1-D phenotype. <i>European Journal of Paediatric Neurology</i> , 2018 , 22, 345	3.8	0
169	Inferring the effect of genomic variation in the new era of genomics. 2018 , 39, 756-773		19
168	Acetazolamide-responsive Episodic Ataxia Without Baseline Deficits or Seizures Secondary to GLUT1 Deficiency: A Case Report and Review of the Literature. 2018 , 23, 17-18		7
167	Inborn Errors of Metabolism with Seizures: Defects of Glycine and Serine Metabolism and Cofactor-Related Disorders. 2018 , 65, 279-299		5
166	Three novel SLC2A1 mutations in Bulgarian patients with different forms of genetic generalized epilepsy reflecting the clinical and genetic diversity of GLUT1-deficiency syndrome. 2018 , 54, 41-44		3
165	Phenotype variability of GLUT1 deficiency syndrome: Description of a case series with novel SLC2A1 gene mutations. 2018 , 79, 169-173		5
164	A frame-shift deletion in the PURA gene associates with a new clinical finding: Hypoglycorrachia. Is GLUT1 a new PURA target?. 2018 , 123, 331-336		14
163	Paroxysmal Dyskinesias. 2018 , 25, 75-81		10
162	Stroke mimics add to the phenotypic spectrum of GLUT1 deficiency syndrome. 2018 , 89, 668-670		5
161	10 patients, 10 years - Long term follow-up of cardiovascular risk factors in Glut1 deficiency treated with ketogenic diet therapies: A prospective, multicenter case series. 2018 , 37, 2246-2251		25
160	A critique of the alternating access transporter model of uniport glucose transport. 2018 , 4, 287-299		7
159	Investigation of SLC2A1 gene variants in genetic generalized epilepsy patients with eyelid myoclonia. 2018 , 20, 396-400		2
158	Development of a rapid functional assay that predicts GLUT1 disease severity. 2018 , 4, e297		5
157	Mutations in Disordered Regions Can Cause Disease by Creating Dileucine Motifs. 2018 , 175, 239-253.e17		58
156	Cognitive benefits of the ketogenic diet in patients with epilepsy: A systematic overview. 2018 , 87, 69-77		30

155	The expanding spectrum of paroxysmal movement disorders: update from clinical features to therapeutics. 2018 , 31, 491-497	14
154	Genetic Analysis of Signal Generation by the Rgt2 Glucose Sensor of. 2018 , 8, 2685-2696	6
153	Atassie episodiche. 2018 , 18, 1-7	
152	Long-Term Effect of GPi-DBS in a Patient With Generalized Dystonia Due to GLUT1 Deficiency Syndrome. 2018 , 9, 381	2
151	Individualizing Treatment Approaches for Epileptic Patients with Glucose Transporter Type1 (GLUT-1) Deficiency. 2018 , 19,	26
150	Paroxysmal ocular movements - an early sign in Glut1 deficiency Syndrome. 2018 , 33, 1381-1383	3
149	Neonatal Seizures. 2018 , 961-970.e4	1
148	Developmental outcomes and prevalence of SLC2A1 variants in young infants with hypoglycorrhachia. 2019 , 41, 854-861	1
147	Quality of Life in Chronic Ketogenic Diet Treatment: The GLUT1DS Population Perspective. 2019 , 11,	6
146	Pharmacogenetics and the treatment of epilepsy: what do we know?. 2019 , 20, 1093-1101	4
145	Overall cognitive profiles in patients with GLUT1 Deficiency Syndrome. 2019 , 9, e01224	20
144	Paroxysmal Movement Disorders: Recent Advances. 2019 , 19, 48	5
143	Diagnosis and management of progressive ataxia in adults. 2019 , 19, 196-207	20
142	Failure of ketogenic diet therapy in GLUT1 deficiency syndrome. <i>European Journal of Paediatric Neurology</i> , 2019 , 23, 404-409	3.8 14
141	Genetic mimics of cerebral palsy. 2019 , 34, 625-636	44
140	A Revised Mental Energy Hypothesis of the g Factor in Light of Recent Neuroscience. 2019 , 23, 201-210	5
139	Epileptogenesis in Idiopathic Epilepsy. 2019 , 8-23	
138	Approach to the Diagnosis of Epilepsy Syndromes with Multiple Causes. 2019 , 103-111	

137	Long-term follow-up in an open-label trial of triheptanoin in GLUT1 deficiency syndrome: a sustained dramatic effect. 2019 , 90, 1291-1293	12
136	Guidelines on the diagnosis and management of the progressive ataxias. 2019 , 14, 51	26
135	Paroxysmal movement disorders: Recent advances and proposal of a classification system. 2019 , 59, 131-139	8
134	The spectrum of paroxysmal dyskinesias. 2019 , 14, FNL26	5
133	62 Corpus Callosotomy. 2019 ,	
132	Study of paediatric patients with the clinical and biochemical phenotype of glucose transporter type 1 deficiency syndrome. 2019 ,	2
131	Treating Hereditary Ataxias Where Can We Help?. 2019 , 55, 182-188	
130	Analysis of craniofacial character of glucose transporter type I deficiency syndrome. 2019 , 78, 151-159	
129	Movement Disorders in Treatable Inborn Errors of Metabolism. 2019 , 34, 598-613	32
128	Unravelling of the paroxysmal dyskinesias. 2019 , 90, 227-234	42
127	Epilepsy genetics: clinical impacts and biological insights. 2020 , 19, 93-100	40
126	Hypointensity of the Basal Ganglia in Adults with Glucose Transporter Protein Type 1 Deficiency Syndrome: A Novel Magnetic Resonance Imaging Finding. 2020 , 87, 10-11	0
125	Molecular genetic management of epilepsy. 2020 , 289-308	
124	The expanding spectrum of movement disorders in genetic epilepsies. 2020 , 62, 178-191	15
123	[GLUT1 and COVID-19 deficiency syndrome]. 2021 , 68, 514-515	0
122	Chorea in children: etiology, diagnostic approach and management. 2020 , 127, 1323-1342	9
121	The role of molecular analysis of SLC2A1 in the diagnostic workup of glucose transporter 1 deficiency syndrome. 2020 , 416, 117041	0
120	Glucose transporters in brain in health and disease. 2020 , 472, 1299-1343	95

- 119 Genetic background of ataxia in children younger than 5 years in Finland. **2020**, 6, e444 3
- 118 Neuroenergetics and "General Intelligence": A Systems Biology Perspective. **2020**, 8, 3
- 117 Hemiplegic Migraine in Glut1 Deficiency Syndrome and Paroxysmal Dyskinesia at Ketogenic Diet Induction: Case Report and Literature Review. **2020**, 7, 965-970 2
- 116 The Natural History of Epilepsy. **2020**, 1-13
- 115 Challenges in Identifying Medication-Resistant Epilepsy. **2020**, 14-19
- 114 International League Against Epilepsy's Definition of Medication-Resistant Epilepsy. **2020**, 20-26
- 113 The Economic Impact of Medication-Resistant Epilepsy. **2020**, 27-33
- 112 Social Consequences of Medication-Resistant Epilepsy. **2020**, 34-38
- 111 Mortality and Morbidity of Medication-Resistant Epilepsy. **2020**, 39-50
- 110 Models for Medication-Resistant Epilepsy. **2020**, 51-61
- 109 Neurobiology of Medication-Resistant Epilepsy. **2020**, 62-68
- 108 Genetic Causes of Medication-Resistant Epilepsy. **2020**, 69-78
- 107 Malformations of Cortical Development as Causes of Medication-Resistant Epilepsy. **2020**, 79-86
- 106 Hippocampal Sclerosis as a Cause of Medication-Resistant Epilepsy. **2020**, 87-99
- 105 Autoimmune Causes of Medication-Resistant Epilepsy. **2020**, 100-117
- 104 Medication-Resistant Epilepsy Syndromes in Children. **2020**, 118-157
- 103 Medication-Resistant Epilepsy in Adults. **2020**, 158-170 1
- 102 Approach to the Treatment of Medication-Resistant Epilepsy. **2020**, 171-178

101	Pharmacotherapy for Medication-Resistant Epilepsy. 2020 , 179-186	2
100	Reproductive Health for Women with Medication-Resistant Epilepsy. 2020 , 187-197	
99	Resective Surgery for Medication-Resistant Epilepsy. 2020 , 198-209	
98	Ablative Surgery for Medication-Resistant Epilepsy. 2020 , 210-218	
97	Stimulation Treatment for Medication-Resistant Epilepsy. 2020 , 219-240	
96	Diet Therapy for Medication-Resistant Epilepsy. 2020 , 241-247	
95	Botanical Treatments for Medication-Resistant Epilepsy. 2020 , 248-255	
94	Psychiatric Comorbidities in Medication-Resistant Epilepsy. 2020 , 256-268	
93	Episodic Ataxias: Faux or Real?. 2020 , 21,	0
92	Glucose transporters in pancreatic islets. 2020 , 472, 1249-1272	20
91	Glucose transporter 1 deficiency syndrome: nutritional and growth pattern phenotypes at diagnosis. 2020 , 74, 1290-1298	1
90	Animal Models of Metabolic Epilepsy and Epilepsy Associated Metabolic Dysfunction: A Systematic Review. 2020 , 13,	9
89	Movement Disorders in Genetic Pediatric Ataxias. 2020 , 7, 383-393	2
88	Glucose transporter type 1 deficiency syndrome associated with autoantibodies to glutamate receptors. 2020 , 42, 686-690	
87	A Family With a Complex Phenotype Caused by Two Different Rare Metabolic Disorders: GLUT1 and Very-Long-Chain Fatty Acid Dehydrogenase (VLCAD) Deficiencies. 2020 , 11, 514	1
86	Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group. 2020 , 5, 354-365	45
85	Treatable Inherited Movement Disorders in Children: Spotlight on Clinical and Biochemical Features. 2020 , 7, 154-166	7
84	Treatment of Paroxysmal Dyskinesia. 2020 , 38, 433-447	11

83	Treatable cerebellar ataxias. 2020 , 3, 100053		1
82	Current challenges in the pathophysiology, diagnosis, and treatment of paroxysmal movement disorders. 2021 , 21, 81-97		5
81	Lenticular nuclei to thalamic ratio on PET is useful for diagnosis of GLUT1 deficiency syndrome. 2021 , 43, 69-77		
80	Hypoglycemia in the Newborn and Infant. 2021 , 175-201		0
79	Study of paediatric patients with the clinical and biochemical phenotype of glucose transporter type 1 deficiency syndrome.. 2022 , 37, 91-100		
78	Diagnostic precision and identification of rare diseases is dependent on distance of residence relative to tertiary medical facilities. 2021 , 16, 131		2
77	Precision medicine for genetic childhood movement disorders. 2021 , 63, 925-933		1
76	Paroxysmal Genetic Movement Disorders and Epilepsy. 2021 , 12, 648031		4
75	Classic Ketogenic Diet and Modified Atkins Diet in SLC2A1 Positive and Negative Patients with Suspected GLUT1 Deficiency Syndrome: A Single Center Analysis of 18 Cases. 2021 , 13,		2
74	How to detect late-onset inborn errors of metabolism in patients with movement disorders - A modern diagnostic approach. 2021 , 85, 124-132		1
73	Characterization of Speech and Language Phenotype in GLUT1DS. 2021 , 8,		3
72	A Systematic Review of Glucose Transport Alterations in Alzheimer's Disease. 2021 , 15, 626636		8
71	Sub-genic intolerance, ClinVar, and the epilepsies: A whole-exome sequencing study of 29,165 individuals. 2021 , 108, 965-982		6
70	SLC2A1 and Its Related Epileptic Phenotypes.		0
69	CACNA1A-associated epilepsy: Electroclinical findings and treatment response on seizures in 18 patients. <i>European Journal of Paediatric Neurology</i> , 2021 , 33, 75-85	3.8	5
68	Genetics of Paroxysmal Dyskinesia: Novel Variants Corroborate the Role of in Paroxysmal Dyskinesia and Highlight the Diverse Phenotypic Spectrum of - and -Related Disorders. 2021 , 12, 701351		0
67	GLUT1 Deficiency Syndrome-Early Treatment Maintains Cognitive Development? (Literature Review and Case Report). <i>Genes</i> , 2021 , 12,	4.2	3
66	Paroxysmal dyskinesias. 2021 , 560-578.e13		

65	Treatable Inborn Errors of Metabolism Causing Intellectual Disability: A Review and Diagnostic Approach.	2
64	Movement Disorders. 2012 , 230-259	2
63	Cerebrospinal fluid glucose and lactate: age-specific reference values and implications for clinical practice. 2012 , 7, e42745	79
62	Understanding the Spectrum of -Associated Disorders. 2017 , 31, 4	2
61	The Genetic Relationship between Paroxysmal Movement Disorders and Epilepsy. 2020 , 28, 76-87	1
60	Glucose transport 1 deficiency presenting as infantile spasms with a mutation identified in exon 9 of. 2016 , 59, S29-S31	5
59	Diagnostic Challenges Associated with GLUT1 Deficiency: Phenotypic Variabilities and Evolving Clinical Features. 2019 , 60, 1209-1215	8
58	Clinical and Genetic Overview of Paroxysmal Movement Disorders and Episodic Ataxias. 2020 , 21,	19
57	Unusual phenotype of glucose transport protein type 1 deficiency syndrome: A case report and literature review. 2014 , 9, 36-8	1
56	Glucose Transporter Type 1 Deficiency Syndrome: Developmental Delay and Early-Onset Ataxia in a Novel Mutation of the Gene. 2018 , 13, 496-499	1
55	Expanding Genetic and Clinical Spectrum of GLUT1D. 2010 , 24, 26	
54	Nonepileptic Paroxysms in Neonates, Infants and Adolescents. 2012 , 234-247	
53	Ketogenic Dietary Therapy in Neurometabolic Disease. 220-224	
52	Neurometabolic Crisis. 2014 , 147-158	
51	Störungen des Monosaccharidstoffwechsels. 2014 , 493-509	
50	Angeborene Störungen des Kohlenhydratstoffwechsels und sonstige angeborene Stoffwechselstörungen. 2014 , 117-132	
49	A Case Report of Glucose Transporter 1 Deficiency Syndrome with a Novel Splice Site Mutation (SLC2A1: c.680-2delA). 2014 , 22, 182-185	
48	Genetische Defekte des Monosaccharidstoffwechsels. 2015 , 1-25	

47	Clinical Variability of GLUT1DS. 2015 , 29, 14		
46	Patterned or Repetitive Movements and/or Abnormal Posturing. 2016 , 265-303		
45	Disorders of Glucose Transport. 2016 , 175-183		2
44	Genetische Defekte des Monosaccharidstoffwechsels. 2019 , 1-21		
43	Impact of pathogenic mutations of the GLUT1 glucose transporter on channel dynamics using ConsDYN enhanced sampling. <i>F1000Research</i> , 8, 322		3.6
42	Glucose Transporter 1 deficiency and associated conditions in children. 2019 , 64, 155-158		
41	Index. 2020 , 269-274		
40	Medication-Resistant Epilepsy: Diagnosis and Treatment. 2020 ,		
39	Ketogenic Diet. 2021 , 271-277		
38	Treatable Metabolic Epilepsies. 2020 , 917-927		
37	Genetische Defekte des Monosaccharidstoffwechsels. 2020 , 705-725		
36	Movement Disorders and Inherited Metabolic Disorders. 2020 ,		1
35	Paroxysmal Exercise-Induced Dyskinesia. 2021 , 55-61		
34	Pathophysiology of Paroxysmal Dyskinesia. 2021 , 95-108		
33	GLUT1 and COVID-19 deficiency syndrome. <i>Endocrinología y Diabetes y Nutrición (English Ed)</i> , 2021 , 68, 514-515		0.1
32	Clinical and Genetic Characteristics of Chinese Children With GLUT1 Deficiency Syndrome: Case Report and Literature Review. <i>Frontiers in Genetics</i> , 2021 , 12, 734481		4.5 1
31	Glukosetransporter(Glut1)-Defekt. <i>Padiatrie Und Padologie</i> , 2022 , 57, 16		0
30	Diagnostic and Clinical Manifestation Differences of Glucose Transporter Type 1 Deficiency Syndrome in a Family with SLC2A1 Gene Mutation.. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19,		4.6

29	Evidence That Substantia Nigra Pars Compacta Dopaminergic Neurons Are Selectively Vulnerable to Oxidative Stress Because They Are Highly Metabolically Active.. <i>Frontiers in Cellular Neuroscience</i> , 2022 , 16, 826193	6.1	2
28	The clinical and biochemical hallmarks generally associated with GLUT1DS may be caused by defects in genes other than SLC2A1.. <i>Clinical Genetics</i> , 2022 ,	4	1
27	Diverse Molecular Mechanisms Underlying Pathogenic Protein Mutations: Beyond the Loss-of-Function Paradigm.. <i>Annual Review of Genomics and Human Genetics</i> , 2022 ,	9.7	4
26	Novel CSF biomarkers of GLUT1 deficiency syndrome: implications beyond the brain's energy deficit.		
25	Treatment and Management of Autosomal Recessive Cerebellar Ataxias: Current Advances and Future Perspectives.. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022 ,	2.6	
24	Data_Sheet_1.DOCX. 2018 ,		
23	Video_1.MOV. 2018 ,		
22	Video_2.MOV. 2018 ,		
21	Video_3.MOV. 2018 ,		
20	Long-term outcome of developmental and epileptic encephalopathies.. <i>Revue Neurologique</i> , 2022 ,	3	
19	Head circumference in glucose transporter 1 deficiency syndrome: Normal for individuals, abnormal as a group.. <i>European Journal of Paediatric Neurology</i> , 2022 , 38, 73-76	3.8	
18	Blood-brain barrier targeted delivery of lacosamide-conjugated gold nanoparticles: Improving outcomes in absence seizures. <i>Epilepsy Research</i> , 2022 , 106939	3	0
17	ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions.. <i>Epilepsia</i> , 2022 ,	6.4	15
16	An overview on metabolic disorders and current therapy. 2022 , 3-33		
15	Impact of pathogenic mutations of the GLUT1 glucose transporter on solute carrier dynamics using ComDYN enhanced sampling. <i>F1000Research</i> , 8, 322	3.6	
14	GLUT1-deficiency syndrome. <i>Neurologie Pro Praxi</i> , 2022 , 23, 120-123	0.2	
13	Phenotypic and Genotypic Spectrum of Early-Onset Developmental and Epileptic Encephalopathies Data from a Romanian Cohort. <i>Genes</i> , 2022 , 13, 1253	4.2	
12	An in vitro model of glucose transporter 1 deficiency syndrome at the bloodBrain barrier using induced pluripotent stem cells.		1

- 11 Molecular genetics of GLUT1DS Italian pediatric cohort: 10 novel related-disease variants and structural analysis. ○
- 10 Novel CSF biomarkers of GLUT1 deficiency syndrome: implications beyond the brain's energy deficit. ○
- 9 Neuropsychological Outcome of Glucose Transporter-1 Deficiency Syndrome: a Case Study of Identical Twin Boys Without Intellectual Disability. ○
- 8 Molecular Genetics of GLUT1DS Italian Pediatric Cohort: 10 Novel Disease-Related Variants and Structural Analysis. **2022**, 23, 13560 ○
- 7 Perioperative management of surgical orthodontic treatment in a patient with glucose transporter 1 deficiency: report of a case and review of the literature. **2022**, 11, ○
- 6 Establishment of a flow cytometry screening method for patients with glucose transporter 1 deficiency syndrome. **2023**, 34, 100954 ○
- 5 Metabolic contributions to neuronal deficits caused by genomic disruption of schizophrenia risk gene SETD1A. **2022**, 8, ○
- 4 Genetic Links to Episodic Movement Disorders: Current Insights. Volume 16, 11-30 ○
- 3 Autosomal Recessively Inherited Glucose Transporter-1 Deficiency Syndrome with Acanthocytosis: A Case Report. ○
- 2 Timing of Ketogenic Dietary Therapy (KDT) Introduction and Its Impact on Cognitive Profiles in Children with Glut1-DSA Preliminary Study. **2023**, 10, 681 ○
- 1 Association between cerebrospinal fluid parameters and developmental and neurological status in glucose transporter 1 deficiency syndrome. **2023**, 447, 120597 ○